Technologies and Intellectual Property

SPY Imaging Technology

Novadaq’s SPY Imaging technology platform combines solid state illumination and high-resolution real-time imaging using sophisticated camera technology, proprietary image analysis and management software, and a proven safe, injectable fluorescing imaging agent. Together these components produce clinically relevant images of blood flow in vessels, micro-vessels and tissue perfusion during a wide variety of complex surgical and outpatient procedures. SPY technology is flexible and has been used to develop unique imaging devices specifically designed to meet the needs of different physicians and the specialty procedures they perform. Use of SPY technology allows effective visualization of critical anatomy and blood perfusion in tissue and organs without exposing the patient or staff to potentially harmful ionizing radiation. The ability to visually assess the quality of blood flow and tissue perfusion in real-time enables clinicians treating life-threatening illnesses to both avoid conditions that could lead to damage to healthy tissue and organs and also to remove poorly perfused tissue that could otherwise lead to serious and costly complications.

More than 70 peer-reviewed publications report experiences using SPY Imaging technologies in a variety of surgical procedures including open, robotic and endoscopic surgeries. SPY technology is FDA cleared for use in coronary artery bypass, cardiovascular, plastic, reconstructive, micro, organ transplant, gastrointestinal and minimally invasive surgery.


Onco-LIFE Autofluorescence Endoscopic Technology

Onco-LIFE technology enables physicians to quickly and accurately distinguish between healthy and diseased tissue on the basis of differences in intrinsic tissue fluorescence (i.e. without the use of an exogenously applied imaging agent). In an international multi-center clinical trial, the use of Onco-LIFE autofluorescence examination in conjunction with white light imaging demonstrated a 325% improvement in the detection of early lung cancer on a per lesion basis and a 250% improvement in detection of early disease on a per-patient basis when compared to examination by white light alone. In 2007, the American College of Chest Physicians (ACCP) recommended the use of autofluorescence examination to aid diagnosis in instances of radiologically occult lung cancer, as an adjunct to endobronchial therapy and as a tool in the monitoring of patients with known pre-cancers and early cancers.

Onco-LIFE autofluorescence is FDA PMA approved for use in bronchoscopy. Novadaq sees the potential to expand the use of Onco-LIFE into the colon, bladder, uterus and other hollow organs.

Lung cancer - severe dysplasia:

Nerve Imaging

Novadaq is developing molecules which selectively localize to nerves and fluoresce when imaged with SPY technology devices. The proprietary imaging agent is currently in pre-clinical development, with the goal of moving into clinical testing for use during neurosurgeries and nerve-sparing surgeries.

Nerve visualization in animal model


Novadaq aggressively pursues intellectual property protection for its innovations, products and core imaging technologies in all significant markets around the world. The company's current IP portfolio includes more than 100 granted or allowed patents and almost as many pending patent applications which, together, represent more than 45 distinct patent families. Issued patents and pending applications serve as a foundational platform to protect Novadaq innovations and products in a wide array of future applications. In addition to developing intellectual property internally, Novadaq has entered into strategic alliances and joint ventures with universities, research organizations and industry partners who have contributed to Novadaq’s intellectual property through mutually beneficial licensing agreements.


Novadaq takes all active steps afforded under international intellectual property laws to protect and prevent unauthorized use of its trademark assets. The company's current portfolio includes both unregistered and registered trademarks filed with the United States Patent and Trademark Office and the Canadian Intellectual Property Office.